https://orcid.org/0000-0002-3153-4166
References
- Sholjakova M , DurnevV , KartalovA , KuzmanovskaB. Pain relief as an integral part of the palliative care. Open Access Maced. J. Med. Sci.6(4), 739–741 (2018).
- Byock I . Taking psychedelics seriously. J. Palliat. Med.21(4), 417–421 (2018).
- Dutta V . Repression of death consciousness and the psychedelic trip. J. Cancer Res. Ther.8(3), 336–342 (2012).
- Liester MB . A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects. Curr. Drug Abuse Rev.7(3), 146–156 (2014).
- Das S , BarnwalP , RamasamyA , SenS , MondalS. Lysergic acid diethylamide: a drug of ‘use’?Ther. Adv. Psychopharmacol.6(3), 214–228 (2016).
- Bogenschutz MP , RossS. Therapeutic applications of classic hallucinogens. Curr. Top. Behav. Neurosci.36, 361–391 (2018).
- LSD used as analgesic. JAMA187(1), A33 (1964).
- Whelan A , JohnsonMI. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?Pain Manag.8(3), 217–229 (2018).
- Bradley JR . TNF-mediated inflammatory disease. J. Pathol.214(2), 149–160 (2008).
- De Gregorio D , PosaL , Ochoa-SanchezRet al. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol. Res.113(Pt A), 81–91 (2016).
- Dos Santos RG , OsórioFL , CrippaJAS , HallakJEC. Classical hallucinogens and neuroimaging: a systematic review of human studies: hallucinogens and neuroimaging. Neurosci. Biobehav. Rev.71, 715–728 (2016).
- Brewer JA , GarrisonKA. The posterior cingulate cortex as a plausible mechanistic target of meditation: findings from neuroimaging. Ann. NY Acad. Sci.1307, 19–27 (2014).
- Allen M , DietzM , BlairKSet al. Cognitive-affective neural plasticity following active-controlled mindfulness intervention. J. Neurosci.32(44), 15601–15610 (2012).
- Fields HL . Understanding how opioids contribute to reward and analgesia. Reg. Anesth. Pain Med.32(3), 242–246 (2007).
- Mitsi V , ZachariouV. Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience338, 81–92 (2016).
- Buckner RL , Andrews-HannaJR , SchacterDL. The brain’s default network: anatomy, function, and relevance to disease. Ann. NY Acad. Sci.1124, 1–38 (2008).
- Kast EC , CollinsVJ. Study of lysergic acid diethylamide as an analgesic agent. Anesth. Analg.43, 285–291 (1964).
- Kast E . Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatr. Q.41(4), 646–657 (1967).
- Grof S , GoodmanLE , RichardsWA , KurlandAA. LSD-assisted psychotherapy in patients with terminal cancer. Int. Pharmacopsychiatry8(3), 129–144 (1973).
- Pahnke WN , KurlandAA , GoodmanLE , RichardsWA. LSD-assisted psychotherapy with terminal cancer patients. Curr. Psychiatr. Ther.9, 144–152 (1969).
- Fanciullacci M , BeneED , FranchiG , SicuteriF. Brief report: phantom limp pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25). Headache17(3), 118–119 (1977).
- Schindler EAD , GottschalkCH , WeilMJ , ShapiroRE , WrightDA , SewellRA. Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. J. Psychoactive Drugs47(5), 372–381 (2015).
- Sewell RA , HalpernJH , PopeHG. Response of cluster headache to psilocybin and LSD. Neurology66(12), 1920–1922 (2006).
- Cohen S , DitmanKS. Complications associated with lysergic acid diethylamide (LSD-25). JAMA181, 161–162 (1962).
- Winkelman M . Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Curr. Drug Abuse Rev.7(2), 101–116 (2014).